NCT05044325View on ClinicalTrials.gov

A First Time in Human (FTIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK3884464 in Healthy Participants

PHASE1TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

September 20, 2021

Primary Completion Date

August 5, 2022

Study Completion Date

August 5, 2022

Conditions
Heart Failure
Interventions
DRUG

GSK3884464

GSK3884464 will be administered

DRUG

Placebo

Placebo to match GSK3884464 will be administered.

Trial Locations (1)

CB2 2GG

GSK Investigational Site, Cambridge

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY